Multiple Sclerosis News and Research RSS Feed - Multiple Sclerosis News and Research

Multiple sclerosis (MS) is a severe autoimmune disease of the central nervous system that affects the brain and spinal cord, causing problems with muscle movement, balance and vision.

In MS, the protein coating called myelin, which protects nerves and helps electrical signals travel from the brain to the rest of the body, is damaged. The immune system, which usually fights infection, mistakes myelin for a foreign body and attacks it, stripping it from around the nerves. Exactly what causes this abnormal immune response is unclear, but research suggests a combination of both genetic and environmental factors.

The damaged myelin disrupts the transfer of nerve signals which may slow down, become distorted or stop altogether. This can cause severe symptoms ranging from vision loss through to muscle stiffness, loss of control over muscle movement, difficulties with balance and poor co-ordination.

Around 100,000 people in the UK have MS and it affects about three times as many women as men. The usual age at which diagnosis occurs is around 30, however, symptoms often first develop between the ages of 15 and 45.

Currently, there is no cure for MS but therapeutic approaches such as physiotherapy and steroid injections are used to manage the condition and ease symptoms.
Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. [More]
Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS). [More]
Study identifies novel gene that controls nerve conduction velocity linked with MS

Study identifies novel gene that controls nerve conduction velocity linked with MS

A new study published in The American Journal of Pathology identifies a novel gene that controls nerve conduction velocity. [More]
Study examines the influence of unexpected task constraint on voluntary task switching

Study examines the influence of unexpected task constraint on voluntary task switching

Kessler Foundation scientists have published results of cognitive research that show the negative effects that unexpected task constraint, following self-generated task choice, has on task-switching performance. [More]
Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, in Washington D.C. [More]
Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus. [More]
Global therapeutic market for BBB technologies expected to grow at 64.9% CAGR over 2014-2019

Global therapeutic market for BBB technologies expected to grow at 64.9% CAGR over 2014-2019

Reportlinker.com announces that a new market research report is available in its catalogue: Blood-Brain Barrier Technologies and Global Markets. [More]

Forward Pharma files Form F-1 registration statement for initial public offering of shares

Forward Pharma A/S, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares. [More]
Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. [More]
Longer looks: Kentucky is health law poster child; how to negotiate a lower medical bill; the Ebola outbreak up close

Longer looks: Kentucky is health law poster child; how to negotiate a lower medical bill; the Ebola outbreak up close

About a year ago, on Aug. 22, a team of inspectors from the Centers for Medicare and Medicaid Services (CMS) unit of the U.S. Department of Health and Human Services arrived in Frankfort, Ky., to see if the people working out of a nondescript warehouse there were going to be able to pull off the launch of Kentucky's Obamacare health-insurance exchange. [More]
Dimethyl fumarate offers no added benefits for adults with RRMS

Dimethyl fumarate offers no added benefits for adults with RRMS

Dimethyl fumarate has been approved since January 2014 for adults with relapsing remitting multiple sclerosis. [More]
United Spinal partners with Airshells to provide access to safety bags for people living with disabilities

United Spinal partners with Airshells to provide access to safety bags for people living with disabilities

August 6th, United Spinal Association today announced a partnership with Airshells.us to provide people living with disabilities access to safety bags designed to protect foldable and rigid wheelchairs from damage during air travel. [More]
Low levels of vitamin D may double dementia, Alzheimer's risks

Low levels of vitamin D may double dementia, Alzheimer's risks

In the largest study of its kind, researchers suggests that in older people, not getting enough vitamin D may double the risk of developing dementia and Alzheimer's disease. The study is published in the August 6, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Research may aid efforts to help patients recover from spinal cord injuries

Research may aid efforts to help patients recover from spinal cord injuries

Researchers in the Vanderbilt University Institute of Imaging Science (VUIIS) have achieved the first conclusive non-invasive measurement of neural signaling in the spinal cords of healthy human volunteers. [More]
Costly specialty drugs drive up Medicare tab

Costly specialty drugs drive up Medicare tab

ProPublica and The New York Times look at the explosive spending growth from an obscure medication for treating multiple sclerosis and a rare kidney disease -- and how several top prescribers have links to drugmaker, Questcor Pharmaceuticals. [More]
Kessler Foundation, Kessler Institute participate in NIH StrokeNet via Columbia University

Kessler Foundation, Kessler Institute participate in NIH StrokeNet via Columbia University

A new network of 25 regional stroke centers and satellite facilities - the NIH Stroke Trials Network - is working to change the way stroke research is conducted in the U.S. Despite advances of the last two decades, stroke remains a major public health problem. [More]
Researchers confirm for the first time that achalasia is autoimmune in origin

Researchers confirm for the first time that achalasia is autoimmune in origin

Achalasia is a rare disease - it affects 1 in 100,000 people - characterized by a loss of nerve cells in the esophageal wall. [More]
Massage therapy can alleviate symptoms of multiple sclerosis

Massage therapy can alleviate symptoms of multiple sclerosis

An estimated 2.3 million people worldwide live with multiple sclerosis (MS) each day, a debilitating disease that can often cause severe pain, muscle spasms, poor circulation, anxiety, stress and clinical depression. [More]
Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Today Biogen Idec announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). [More]
Immune system play role in memory impairment associated with chronic epilepsy

Immune system play role in memory impairment associated with chronic epilepsy

Could the body's own immune system play a role in memory impairment and cognitive dysfunction associated with conditions like chronic epilepsy, Alzheimer's dementia and concussions? Cleveland Clinic researchers believe so, based on a study published online by PLOS ONE. [More]